Tonix Pharmaceuticals Holding short interest in 2021
In 2021, Tonix Pharmaceuticals Holding's disclosed short interest ran from 1.21% of shares outstanding on 15 Mar 2021 to 2.28% on 31 Dec 2021, a change of +1.07 percentage points. The year's high was 5.59% on 30 Jun 2021 and its low 1.21% on 15 Mar 2021, averaging 2.50% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 1.87 days on 15 Jul 2021. Full history: Tonix Pharmaceuticals Holding.
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2025 · 2026
2021 in figures
- Start of year
- 1.21% (15 Mar 2021)
- End of year
- 2.28% (31 Dec 2021)
- Change
- +1.07 pp
- High
- 5.59% (30 Jun 2021)
- Low
- 1.21% (15 Mar 2021)
- Average
- 2.50%
- Highest days to cover
- 1.87 (15 Jul 2021)
- SEC filings marked
- 8
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Mar 2021 | 1.21% | 1.00 | 10-K filed, results (8-K) |
| 31 Mar 2021 | 1.74% | 1.00 | |
| 15 Apr 2021 | 1.41% | 1.00 | |
| 30 Apr 2021 | 1.76% | 1.00 | |
| 14 May 2021 | 1.63% | 1.00 | 10-Q filed, results (8-K) |
| 28 May 2021 | 1.79% | 1.00 | |
| 15 Jun 2021 | 2.60% | 1.00 | |
| 30 Jun 2021 | 5.59% | 1.06 | |
| 15 Jul 2021 | 3.60% | 1.87 | |
| 30 Jul 2021 | 4.93% | 1.49 | |
| 13 Aug 2021 | 3.89% | 1.36 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 3.28% | 1.00 | |
| 15 Sep 2021 | 2.78% | 1.00 | |
| 30 Sep 2021 | 2.65% | 1.00 | |
| 15 Oct 2021 | 1.75% | 1.00 | |
| 29 Oct 2021 | 1.75% | 1.00 | |
| 15 Nov 2021 | 1.41% | 1.00 | 10-Q filed, results (8-K) |
| 30 Nov 2021 | 1.97% | 1.00 | |
| 15 Dec 2021 | 1.97% | 1.00 | |
| 31 Dec 2021 | 2.28% | 1.00 |
See also: Tonix Pharmaceuticals Holding's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.